Johnson & Johnson to acquire Ollin Biosciences for $2.2 billion
Johnson & Johnson has agreed to purchase Ollin Biosciences, a clinical-stage biopharmaceutical company focused on treatments for serious eye diseases, in a deal valued at $2.2 billion. The acquisition would bring Ollin's pipeline of ophthalmology therapies under J&J's umbrella.